Camazepam
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 90% |
Metabolism | Hepatic |
Elimination half-life | 6,4-10,5 hours |
Excretion | Renal |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Camazepam
Pharmacology
Camazepam, like others benzodiazepines, produce a variety of therapeutic and adverse effects by binding to the benzodiazepine receptor site on the
Pharmacokinetics
Following oral administration, camazepam is almost completely absorbed into the bloodstream, with 90 percent bioavailability achieved in humans.[13] In the human camazepam is metabolised into the active metabolite temazepam.[14] Studies in dogs have shown that the half-life of the terminal elimination phase ranged from 6.4 to 10.5 h.[15]
Medical uses
Camazepam is indicated for the short-term treatment of insomnia and anxiety.[16] As with other benzodiazepines, its use should be reserved for patients in which the sleep disorder is severe, disabling, or causes marked distress.[17]
Adverse effects
With higher doses, such as 40 mg of camazepam, impairments similar to those caused by other benzodiazepines manifest as disrupted
Research has demonstrated that Camazepam exhibits competitive binding to benzodiazepine receptors within the brain, albeit with a relatively modest affinity in animal models. This interaction with benzodiazepine receptors, facilitated by both Camazepam and its active metabolites, is accountable for the medication's anticonvulsant properties.[1]
Contraindications
Use of camazepam is contraindicated in subjects with known hypersensitivity to drug or allergy to other drugs in the benzodiazepine class or any excipients contained in the pharmaceutical form. Use of camazepam should be avoided or carefully monitored by medical professionals in individuals with the following conditions:
See also
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ DE 2142181, "1,4 Benzodiazepine derivatives and process for their production", issued 23 December 1976, assigned to Siphar S A , Lugano (Schweiz).
- PMID 23793.
- PMID 7911374.
- PMID 8981061.
- PMID 8909973.
- S2CID 24492818.
- PMID 241014.
- PMID 6106497.
- S2CID 28921744.
- PMID 6146112.
- PMID 6144807.
- PMID 2868575.
- PMID 6120096.
- PMID 6127087.
- ^ "Camazepam (PIM 678)". inchem.org. Retrieved 2021-09-09.
- ^ "Camazepam". PubChem. U.S National Library of Medicine. Retrieved 2021-09-09.
- PMID 6120717.
- PMID 6145108.
- S2CID 260193671.
- PMID 27764523.